The development of type 2 diabetes (T2D) in an incident population of patients with psoriatic arthritis (PsA) is significantly higher than in psoriasis alone or in a general population, according to a recent study, whereas the increased risk of cardiovascular disease in PsA and psoriasis is similar. Incident PsA patients aged 18–89 years were identified in a clinical practice research databank between 1998 and 2014 and were matched (1:4 ratio) to a general population cohort and psoriasis cohort. The incidence of T2D, cerebrovascular disease, ischemic heart disease, and peripheral vascular disease (PVD) was calculated for each study cohort. Researchers found:
- 6,783 incident cases of PsA were identified.
- The risk of T2D was significantly higher in the PsA cohort than in the general population and the psoriasis cohorts.
- The incidence of ischemic heart disease, peripheral vascular disease, and the 3 cardiovascular outcomes combined in the PsA cohort was significantly higher than in the general population.
- No significant differences in risk were observed between the PsA and psoriasis cohorts for any cardiovascular outcome.
Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: A population-based cohort study. [Published online ahead of print September 6, 2018]. Rheumatology (Oxford). doi:10.1093/rheumatology/key286.
This Week's Must Reads
CCP Level and Progression to Rheumatoid Arthritis, Arthritis Care Res; ePub 2018 Dec 20; Ford, et al
Evaluation of Cytokine Profile in Patients with RA , Clin Rheumatol; ePub 2018 Dec 1; Alex, et al
Personalized Chronic Disease Risk Tool Evaluated, Patient Educ Couns; ePub 2017 Dec 10; Marshall, et al
10-Year Cardiovascular Risk Assessment in RA, Arthritis Res Ther; ePub 2018 Dec 3; Bissell, et al
Alcohol Use Habits of Patients with RA Evaluated, BMJ Open; 2018 Dec 14; Larsson, et al
Must Reads in Psoriatic arthritis
Assessing Back Pain Criteria in Psoriatic Arthritis, Ann Rheum Dis; 2018 Nov; Yap, Ye, et al
FDA Approves Hyrimoz for Chronic Conditions, Sandoz news release; 2018 Oct 31
T2D Risk in PsA Higher than in General Population , Rheumatology (Oxford); ePub 2018 Sep 6; Charlton, et al
FDA Approves Xeljanz/Xeljanz XR for Adult PsA, Pfizer news release; 2017 Dec 14
FDA Approves New Pfizer Biosimilar Ixifi, Pfizer news release; 2017 Dec 13